Neurofeedback training to improve self-awareness in people with alcohol use disorder
Training Metacognition by Means of Neurofeedback in Subjects With Alcohol Use Disorder Induces Neural Modifications: an Event-related Potentials Study
This study is testing if neurofeedback training can help people with alcohol use disorder become more self-aware and reduce their drinking by improving their thinking skills.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 130 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Brugmann University Hospital Academic / other |
| Locations | 1 site (Brussels) |
| Trial ID | NCT05913518 on ClinicalTrials.gov |
What this trial studies
This study aims to address cognitive deficits associated with alcohol use disorder (AUD) by utilizing neurofeedback training to enhance metacognitive functioning. Participants will undergo a detoxification program while receiving either active neurofeedback or a placebo. The goal is to promote self-awareness and self-regulation, which may help reduce harmful drinking behaviors and prevent relapse. The study seeks to validate neurofeedback as a complementary tool in the treatment of AUD.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 who are undergoing detoxification for severe alcohol use disorder.
Not a fit: Patients with a history of neurological disorders or serious medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve recovery outcomes for patients with alcohol use disorder by enhancing their self-regulation and awareness.
How similar studies have performed: While the use of neurofeedback in treating various conditions has shown promise, this specific application in alcohol use disorder is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged between 18 and 65 years old undergoing a 3- to 4-week detoxification treatment program at the Alcohol Unit of CHU Brugmann hospital (Brussels, BELGIUM), who have been diagnosed with severe AUD (alcohol use disorder) according to the DSM-V-TR. Exclusion Criteria: * history of neurological disorders * other serious medical conditions * neuroleptic treatment are excluded.
Where this trial is running
Brussels
- CHU Brugmann — Brussels, Belgium (Recruiting)
Study contacts
- Principal investigator: Salvatore Campanella — CHU Brugmann
- Study coordinator: Salvatore Campanella
- Email: salvatore.campanella@chu-brugmann.be
- Phone: 3224772705
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.